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INTRODUCTION
Lung cancer is one of the most lethal malignant tumors
with more than 1.3 million estimated deaths annually. In the
United States, approximately 175,000 new cases are diagnosed
each year, 75-80% of which are non-small cell lung cancer (1).
In 2004, it has been estimated that there will be 68,200 lung
cancer deaths among women and 93,100 among men; there
appears to be a leveling off in the incidence of lung cancer
and the death rate among males in the U.S.A. although the
incidence and mortality in females continues to increase (2). 
According to the Korean National Cancer Registry, lung
cancer is the second most common malignant tumor follow-
ing gastric cancer, and accounts for the 11.9% of total num-
ber of newly reported cancers (3). Recently, lung cancer death
rates have continued to increase since 1999 and lung cancer
is the leading cause of all cancer deaths in Korea. Lung can-
cer death rates of Korean population increased from 17.4 per
100,000 in 1993 to 26.4 per 100,000 in 2003, and accounted
for 15.7% of all cancer deaths in 1993 and 20.0% in 2003 (4).
Overall, 5-yr survival rates for lung cancer are about 14%
in the United States and ranges from 5.5% to 14% in the
Europe (5-7). It has been reported that the 5-yr survival rate
after resection of stage IA is more than 70%, whereas that
for stage IV lung cancer is less than 3% (8, 9). 
Trials to reduce mortality rates from lung cancer have been
performed over many years using various methods (10-13).
However, there is no good evidence that screening for lung
cancer by using chest radiography or sputum cytology can re-
duce lung cancer mortality (14). Recently, lung cancer screen-
ing using low-dose CT (LDCT) has been reported to be effec-
tive at detecting small lung cancer (15-17), thus increasing
the expectation that this method will reduce lung cancer mor-
tality. However, in terms of demonstrating definite improve-
ments in cancer mortality, the results of randomized controlled
trials using this screening method are awaited (18). 
The purpose of our study was to assess the overall detection
rates of lung cancers using LDCT screening and to compare
differences in the histopathologic and imaging findings of
detected cancers between asymptomatic Korean high-risk
and low-risk groups.
MATERIALS AND METHODS
Study population
From August 1999 to September 2003, 6,406 individu-
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Lung Cancer Screening with Low-Dose Helical CT in Korea: 
Experiences at the Samsung Medical Center
To determine overall detection rates of lung cancer by low-dose CT (LDCT) screen-
ing and to compare histopathologic and imaging differences of detected cancers
between high- and low-risk groups, this study included 6,406 asymptomatic Kore-
an adults with ≥45 yr of age who underwent LDCT for lung cancer screening. All
were classified into high- (≥20 pack-year smoking; 3,353) and low-risk (3,053; <20
pack-yr smoking and non-smokers) groups. We compared CT findings of detected
cancers and detection rates between high- and low-risk. At initial CT, 35% (2,255
of 6,406) had at least one or more non-calcified nodule. Lung cancer detection
rates were 0.36% (23 of 6,406). Twenty-one non-small cell lung cancers appeared
as solid (n=14) or ground-glass opacity (GGO) (n=7) nodules. Cancer likelihood
was higher in GGO nodules than in solid nodules (p<0.01). Fifteen of 23 cancers
occurred in high-risk group and 8 in low-risk group (p=0.215). Therefore, LDCT
screening help detect early stage of lung cancer in asymptomatic Korean popula-
tion with detection rate of 0.36% on a population basis and may be useful for dis-
covering early lung cancer in low-risk group as well as in high-risk group.
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als with ≥45 yr of age (mean±SD; 55±6.7, range; 46-85)
underwent LDCT for lung cancer screening. Our institution-
al review board approved the lung cancer screening study,
and written informed consent was obtained from all partici-
pants for the CT study. All subjects were asymptomatic and
none had any history of cancer within the previous 5 yr. They
were 5,530 men and 876 women. We evaluated the individu-
al smoking history with the answer sheets for all participants,
who were classified into two groups; high-risk group who had
smoked 20 pack-years or more and low-risk group who had
smoked less than 20 pack-years or who never smoked.
Screening procedure
All scans were performed on multi- or single-slice CT scan-
ners from lung apex to base without contrast enhancement.
The scanning parameters were 120 kVp and 48 (60 mA/0.8
sec) or 50 (50 mA/1.0 sec) mAs. CT machines with four dif-
ferent detector numbers were used, namely, single-detector
(HiSpeed Advantage scanner, GE Medical Systems, Milwau-
kee, WI, U.S.A.; pitch 1.7:1, 5-mm thickness reconstruction
with 4-mm intervals), four-detector (LightSpeed QXi, GE
Medical Systems; 20-mm beam collimation, beam pitch 1.5,
5-mm thickness reconstruction with 4-mm intervals), eight-
and 16-detector (LightSpeed Ultra or Ultra16, GE Medical
Systems; 20-mm beam collimation, beam pitch 1.375, 5-mm
thickness reconstruction with 4-mm intervals). 
We evaluated all images shown on lung (window width
1,500 HU, window level -700 HU) and mediastinal (window
width 342 HU, window level 56 HU) windows on PACS
(Centricity 1.0, General Electric Medical Systems Integrated
Imaging Solutions, Mt. Prospect, IL, U.S.A.) monitors using
cine mode by one of three chest radiologists (S.C., M.J.C., and
K.S.L. with two years, eight years and 15 yr of experience,
respectively, in thoracic imaging). We assessed the attenua-
tion, size and number of nodules, which were classified into
the three types of attenuation: non-calcified solid, ground-
glass opacity or calcified nodule, and were categorized into
three groups of size according to their greatest dimensions:
<5 mm, 5-10 mm, and >10 mm in diameter. 
For non-calcified nodules detected on baseline CT scans, we
recommended the follow-up protocol: if the detected nodule
was solid and 10 mm or more in diameter, immediate inter-
vention (percutaneous needle biopsy, video-assisted thoraco-
scopic surgery or open lung biopsy) was given to obtain a tis-
sue diagnosis after obtaining thin-section CT scans through-
out the nodule (for the marginal and internal nodule charac-
terization of a nodule; volume scanning using multislice CT,
0.8-sec gantry rotation time, 120 kVp, 90 mA, 2.5-mm beam
collimation, beam pitch 1.375, 2.5-mm thickness reconstruc-
tion with 2.5-mm intervals); if the detected nodule was less
than 10 mm in diameter, patients were recommended to have
followed-up CT scans 6 months after the initial examination.
If the nodule did not show any growth over a follow-up period
of six months, an annual follow-up study was recommended.
For ground-glass opacity (GGO) nodules, if more than 10
mm in diameter, immediate intervention was recommended
after obtaining thin-section CT scans throughout the nodule,
however, if less than 10 mm in diameter, thin-section CT
scans were obtained within a short-term follow-up period of
2 months, then after six-months, and annually thereafter.
Of all subjects, 3,638 subjects underwent LDCT scan only
once, 1,537 subjects twice, 704 subjects three times and 527
subjects four times or more.
Cancer assessment
During screening studies, when a nodule was suggestive
of lung cancer with a diameter exceeding 10 mm, a tissue
diagnosis was established by obtaining tumor tissue. For 21
peripheral nodules, tissue diagnosis was made by trans-tho-
racic needle biopsy in 12 patients, video-assisted thoracoscop-
ic surgery in four, open lung biopsy in two, bronchoscopic
biopsy in two, and sputum cytology in one. In two patients
with small cell lung cancer, diagnosis was made in each by
bronchoscopic biopsy and percutaneous needle biopsy. For
all pathologic specimens, one lung pathologist with nine years
of experience evaluated all histopathologic specimens.
For staging of non-small cell lung cancers (NSCLC), we
used the revised International System for Staging Lung Can-
cer adopted by the American Joint Committee on Cancer
(AJCC) and the Union Internationale Contre le Cancer (UICC)
system (19). For staging of small cell lung cancer (SCLC), we
used the system adopted from the Veterans Affairs Research
Service Lung Group (20).
We also obtained the tumor doubling time of lung cancer
using the maximum diameter and volume of each tumor,
which were determined from initial and follow-up CT images.
Tumor volume (V) was calculated using the following equa-
tion, assuming a spherical form:  
V=[4/3×× a×b×(a+b)/2]×1/8 
where aindicates the maximum tumor diameter and bindi-
cates the minimum tumor diameter. The tumor doubling
time (Td) was calculated using the following equation: 
Td=(T-T0)×log2/logV-logV0
where T-T 0 indicates the length of time between two mea-
surements and V0 and V denote the tumor volumes at these
times (21).
For all patients with lung cancers, we assessed the treat-
ment given to the patients and described the follow-up out-
comes after treatment when available. 
Statistical analysis
Overall lung cancer detection rates were described on an
individual basis and on a detected non-calcified nodule basis.
Rates were also calculated according to stratified subjects’ ages
(≥45 yr, >50 yr, or finally >60 yr). Differences in the preva-404 S. Chong, K.S. Lee, M.J. Chung, et al.
lence of all lung cancers between high- and low-risk groups
were compared using the chi-square test. Differences in the
prevalence of stage IA cancers between high- and low-risk
groups, in the incidence of stage IA cancers between the ini-
tial and follow-up screenings, and in the incidence of lung
cancers between GGO and solid nodules were compared using
the Fisher’s exact test. Differences of tumor doubling time
in high- and low-risk groups were compared by the Mann-
Whitney test. We used the SPSS software package (SPSS
11.0.0, SPSS Inc., Chicago, IL, U.S.A.) and considered to be
statistically significant at a pvalue of <0.05.
RESULTS
Of 6,406 subjects, 3,353 subjects belonged to high-risk
group who had smoked 20 pack years or more (39±15.9
pack years). Low-risk group included 3,053 subjects; 1,581
smokers who smoked less than 20 pack-years (13±4.7 pack
years) and 1,472 non-smokers. All smokers had the mean
smoking history of 33.3 pack years.
Table 1 shows the characteristics of non-calcified nodules
detected on LDCT scans. At CT, 35% (2,255 of 6,406) of
screened subjects had at least one or more non-calcified nod-
ules (n=4,037); 2,085 subjects had 3,783 solid nodules (mean,
1.8 nodules per subject) and 170 subjects 254 GGO nodules
(mean, 1.5 nodules per subject).
Table 2 shows the characteristics of lung cancers detected
on LDCT scans. Twenty-three primary lung cancers were
detected with an overall detection rate of 0.36% (23 of 6,406)
on an individual basis and 0.57% (23 of 4,037) on a non-cal-
cified nodule basis. The prevalence of lung cancer according
Numbers in parenthesis are number of subjects and numbers in bracket are number of nodules per person. GGO, ground-glass opacity.
Total
GGO Solid
Group
<5 mm 5-10 mm >10 mm Total <5 mm 5-10 mm >10 mm Total
High risk 1,887 (950) 191 (144) 28 (26) 2,106 (1120) 46 (21) 65 (50) 26 (23) 137 (94) 2,243 (1,214)
Low risk 1,479 (816) 174 (125) 24 (24) 1,677 (965) 52 (24) 53 (40) 12 (12) 117 (76) 1,794 (1,041)
Total 3,366 (1,766) 365 (269) 52 (50) 3,783 [1.81] (2,085) 98 (45) 118 (90) 38 (35) 254 [1.49] (170) 4,037 [1.79] (2,255)
Table 1. Characteristics of non-calcified nodules detected by low-dose screening CT
Td*, doubling time in months; Size
� , size of nodule at initial or final follow-up CT, single number denotes diameter at initial CT; LAP, lymphadenopathy;
RT, radiation therapy; CCRT, concurrent chemoradiation therapy; GGO, ground-glass opacity; BAC, bronchioloalveolar carcinoma; ca, carcinoma;
NA, not applicable.
No. Sex Histologic type TNM staging Group Treatment Outcome
Size
�(mm)
Initial Final
Type of
Attenuation
Td*
(mo)
Age
(yr)
1 M 73 Adenocarcinoma T1N0 IA GGO High Lobectomy Good 9 15 1
2 M 63 Squamous cell ca T1N0 IA Solid High Lobectomy Good 29
3 M 72 Adenocarcinoma T1N0 IA GGO Low No treatment Unknown 6 29 8
4 M 61 Squamous cell ca T2N3 IIIB Solid Low Chemotherapy, Palliative Death, 1 yr later 32
5 M 69 Adenocarcinoma T1N2 IIIA GGO High Lobectomy RT due to recurrence 1 yr later 18
6 M 46 Adenocarcinoma T1N0 IA Solid High Lobectomy Good 10 17 7
7 M 62 SCLC Extensive LAP Low Chemotherapy, Palliative Good NA
8 F 60 Adenocarcinoma T2N3M1 IV Solid Low No treatment Unknown 42
9 M 58 Adenocarcinoma T1N1 IIA Solid High Lobectomy Good 8 18 3
10 M 47 Squamous cell ca T3N2 IIIA Solid High No treatment Unknown 27
11 M 80 Adenocarcinoma T3N1 IIIA Solid High No treatment Death, 3 months later 40
12 F 56 Adenocarcinoma T1N0 IA Solid Low Lobectomy Good 18
13 M 60 Squamous cell ca T2N3M1 IV Solid High No treatment Unknown 34
14 F 60 Adenocarcinoma T1N0 IA Solid Low Lobectomy Good 6 13 3
15 M 54 Adenocarcinoma T1N0 IA Solid Low Lobectomy Pneumonectomy, due to 7 12 49
recurrence 3 yr later
16 M 53 BAC T1N0 IA GGO High Lobectomy Good 9 19 29
17 M 63 BAC T1N0 IA GGO High Lobectomy Good 8 13 27
18 M 56 Adenocarcinoma T1N0 IA GGO High Lobectomy Good 25
19 M 48 Adenocarcinoma T1N0 IA GGO High Lobectomy Good 10 12 21
20 M 61 Squamous cell ca T1N0 IA Solid Low Lobectomy Good 8 13 40
21 M 73 Pleomorphic ca T1N2 IIIA Solid High Lobectomy Good 14 16 3
22 M 56 SCLC Limited LAP High CCRT Good NA
23 M 65 Squamous cell ca T1N0 IA Solid High Lobectomy Good 5 10 3
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to stratified subjects’ ages was 0.36% (23 of 6,406) in those
of ≥45 yr in age, 0.47% (20 of 4,254) in those of >50 yr,
and 0.91% (11 of 1,215) in those of >60 yr.
Adenocarcinoma was found in 12 patients (Fig. 1), squa-
mous cell carcinoma in 6 (Fig. 2), bronchioloalveolar carci-
noma in two, pleomorphic carcinoma in one and small cell
carcinoma in two.
On CT scans, 21 NSCLCs presented as a solid nodule in
14 patients and GGO in seven. The likelihood of lung can-
cer was higher in GGO nodules (7 of 254 GGO nodules, 3%)
than in solid nodules (14/3,783, 0.4%) (p<0.01) (Fisher’s
exact test).
Fig. 1. A 48-yr-old man with adenocarcinoma. (A) Lung window of initial screening low-dose CT scan obtained at level of right upper lobar
bronchus shows 10-mm-sized ground-glass opacity nodule (arrow) in right upper lobe. (B) Lung window of thin-section (2.5-mm thick-
ness) CT scan obtained at similar level to A shows clearly ground-glass opacity nature of nodule (arrow). Right upper lobectomy disclosed
adenocarcinoma.
A B
Fig. 2. A 65-yr-old man with squamous cell carcinoma. (A) Lung window of initial screening low-dose CT (5-mm collimation) scan obtained
at level of bronchus intermedius shows 5-mm-sized nodule (arrow) in bottom of anterior segment of right upper lobe. (B) Repeat CT scan
obtained at same level to and 6 months after A shows interval increase in nodule size (arrow). Right upper lobectomy disclosed squa-
mous cell carcinoma.
A B406 S. Chong, K.S. Lee, M.J. Chung, et al.
The pathologic stages of the 21 NSCLCs were as follows:
T1 in 16 (76%) patients, T2 in 3 (14%), and T3 in 2 (10%);
N0 in 13 (62%), N1 in 2 (10%), N2 in 3 (14%), and N3
in 3 (14%); and stage IA in 13 (62%), IIA in 1 (5%), IIIA
in 4 (19%), IIIB in 1 (5%), and IV in 2 (10%). 
Sixty-five percents (15 of 23) of lung cancers occurred in
high-risk group and 35% (8 of 23) in low-risk group (p=
0.215) (chi-square test). Of 13 stage IA NSCLCs, 8 (57% of
14 NSCLCs in high-risk group) were observed in high-risk
group and 5 (71% of 7 NSCLCs in low-risk group) in low-
risk group (p=0.656) (Fisher’s exact test). 
Of 23 lung cancers, 11 lung cancers were detected during
initial screening and 12 during repeat study. In terms of repeat
studies, 10 lung cancers were detected during the second fol-
low-up study (mean 25.3 months) and 2 during the third
follow-up study (mean 27.3 months). Of 9 NSCLCs detected
at initial screening, three (33%) were stage IA cancers, where-
as of 12 NSCLCs detected at repeat study, 10 (83%) were
stage IA cancers, i.e., stage IA cancers were much more preva-
lent in the repeat study than in the initial study (p=0.032)
(Fisher’s exact test).
Of the 12 lung cancers for which the tumor doubling time
was calculable, the average doubling time was 16±16.7
months (range; 1-49 months). Although this tumor doubling
time was twice as long in low-risk (25±23.2, median; 24,
range; 3-49) group as in high-risk (12±11.9 months, medi-
an; 5.0, range; 1-29) group, it was not statistically significant
(p=0.368) (Mann-Whitney test).
Of 23 patients with lung cancer, lobectomy was performed
in 15. Two patients underwent chemotherapy. Another patient
underwent concurrent chemoradiation therapy. Five patients
were discharged without any therapy because they declined
treatment. Seventeen (74%) of 23 patients were still alive for
4 yr, 2 died, and 4 were lost during follow-up studies. Of the
17 living patients, 15 (65% [15/23]) were alive without tumor
recurrence.
DISCUSSION
Comparisons in inclusion criteria, screening parameters,
and results of LDCT screening for lung cancer are summa-
rized in Table 3 (22-26).
In our study, the proportion (35%) of individuals with non-
calcified nodules was higher than that (23%) reported in the
Early Lung Cancer Action Project (ELCAP) study (24) and
was lower than those (43% and 69%, respectively) reported
in the Germany study by Diederich et al. (26) and in the Mayo
study by Swensen et al. (25), respectively. The difference may
be due to the 5-mm collimation used in the present study
versus 10-mm collimation used in the ELCAP study. How-
ever, the lower detection rates in our study compared to those
of Mayo and German studies (25, 26), although they used the
same 5-mm collimation, cannot be explained simply. Despite
Korea has been known for endemic areas of acute or chronic
granulomatous disease, the reason for this discrepancy is not
clear.
The prevalence of lung cancer in the present study was
0.36% (23 of 6,406) in the study population of ≥45 yr in
age, 0.47% (20 of 4,254) in that of >50 yr, and 0.91% (11
of 1,215) in that of >60 yr. These results of increasing ten-
dency of cancer detection rates with older age are parallel to
those of the German study (26); i.e., 1.5% (12 of 817) in the
study population older than 40 yr, 2.3% (12 of 519) in that
ALCAP, anti-lung cancer association project; ELCAP, early lung cancer action project; SMC, Samsung Medical Center; NL, no limitation; SCLC, small
cell lung cancer; NSCLC, non-small cell lung cancer. Numbers in parenthesis are percentages.
*, reference number; 
� , approximate date that is 6-18 months after baseline screening completed in 1998; 
� , mAs; 
�, number of lung cancer detected
at low-dose CT; 
‖, included both lung cancers considered synchronous primary tumors.
ALCAP (22*) Shinshu (23*) ELCAP (24*) Mayo (25*) Munster (26*) SMC
Age (yr) ≥40 ≥40 ≥60 ≥50 ≥40 ≥45
Smoking habits (pack years) NL NL ≥10 ≥20 ≥20 NL
Period 1993-1998 1996-1998 1993-1999
� 1999-2001 1995-1999 1999-2003
CT protocol
Tube voltage (kVp) 120 120 140 120 120 120
Tube current (mA) 50 25-50 40 40 50
� 48-50
�
Collimation (mm) 10 10 10 5 5 5
Pitch 2 2 2 1.5 2 0.75-1.5
Number of Detector 1 1141 1 , 4 , 8 , 1 6
CT interval (months) 6 12 3, 6, 12 12 3,6,12,24 6, 12
Chest radiograph Yes Yes Yes No No No
Volunteers (total) 1,611 5,483 1,000 1,520 817 6,406
Lung cancer at CT 32
� (2.0) 60 (1.1) 33 (3.3) 38
� (2.5) 12
‖ (1.5) 23 (0.36)
SCLC 1 30312
NSCLC 31 57 33 35 11 21
Stage IA 24 (77) 53 (93) 27 (82) 21 (60) 6 (55) 13 (62)
Table 3. Comparison of inclusion criteria, screening parameters, and the results of low-dose screening CT at various institutionsLung Cancer Screening with Low-Dose Helical CT in Korea 407
older than 50 yr, and 3.9% (8 of 206) in that older than 60
yr. Although the observed prevalence was less in our study, it
is clear that the prevalence of lung cancer in younger popu-
lations is lower. 
Nakata et al. (27) reported that persistent GGO for sever-
al months is an indicator of early adenocarcinoma or its pre-
cursor. The present study showed that nodules showing GGO
on CT scans have a higher risk of harboring lung cancer (2.8%)
than solid nodules (0.37%). Additionally, Kakinuma et al.
(28) evaluated screening CT-detected pure GGO nodules at
follow-up CT and noticed that pure GGO of lung cancer nod-
ule change in size and attenuation over time (GGO nodules
increase in size and solid component appears within GGO
nodule indicating the evolution of pure bronchioloalveolar
carcinoma to adenocarcinoma with bronchioloalveolar carci-
noma component). They recommended close follow-up until
solid component appears for the management of such a focal
GGO. We also emphasize that ‘a short-term follow up and
immediate intervention with growth’ policy are needed for the
management of GGO nodules detected by LDCT screening.
In the current study, 13 (62%) of 21 non-small cell lung
cancers were stage IA. Stage IA cancers were much more fre-
quently detected in the repeat study than in the initial study
(p=0.032). The proportion of stage IA cancers in our study
was higher than those in the Mayo and German Mayo studies,
in which the rates of stage IA were 60% and 55%, respective-
ly (25, 26), but lower than those recorded by the Anti-Lung
Cancer Association Project (ALCAP), Shinshu and ELCAP
studies, in which the rates of stage IA were 77%, 93%, and
82%, respectively (22-24). The high incidence of stage IA
cancer in the ALCAP and Shinshu studies may be due to the
fact that more cancers are detected by repeat study, and thus
less advanced lung cancers are detected. In fact, in the present
study, 57% of detected NSCLCs were discovered by repeat
study, and 31% and 9% in the Mayo and German studies (25,
26), respectively; and 58% and 60% in the ALCAP and Shin-
shu studies (22, 23). Moreover, in ALCAP, Shinshu, ELCAP
and our study, most of stage IA cancers can be detected at
repeat study. Therefore, we suggest that the repeat screening
studies help detect early stage of lung cancer.
Most previous studies have included smokers who have
consumed at least 10 packs a year or more (24-26). However,
in our study and in the Shinshu study (23), subjects of 45 yr
or more of age were included regardless of smoking history.
Our study population was classified into high- and low-risk
groups according to smoking status and evaluated the respec-
tive prevalence of lung cancer accordingly. We found that
there were no significant differences in the prevalence of lung
cancer, doubling time or stage IA of lung cancers between
high- and low-risk groups.
Some limitations of our study should be mentioned. First,
not all patients enrolled in this study were on regular and
recommended followed-up study, therefore there might be
some subjects who had lung cancer after the initial study but
not included in the present study. Second, a single radiolo-
gist read images, and thus some nodules might have been
missed. 
In conclusion, LDCT screening help detect early stage of
lung cancer in asymptomatic Korean population with detec-
tion rate of 0.36% on a population basis and may be useful
for discovering early lung cancer in low-risk group as well
as in high-risk group. The possibility of lung cancer is high-
er when persistent nodular areas of GGO are present at LDCT
than when solid nodules are seen, therefore, a careful follow-
up study should be scheduled for the detection of early lung
cancer.
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